Addition of Multimodal Therapy to Standard Management of Steady State Sickle Cell Disease
Table 3
Steady state levels of plasma thyroid stimulating hormone (TSH) and tri-iodothyronine (T3) in SCD patients before and 12 months after adding omega-3 fatty acids and potassium thiocyanate to standard management with paludrine and folic acid.
Study no.
TSH IU/mL
Free T3 ng/mL
Pretreatment
Posttreatment
Pretreatment
Posttreatment
1
3.65
2.98
0.67
1.4
3
2.25
1.28
0.69
1.14
4
2.31
1.94
0.68
1.2
7
2.84
2.56
0.66
1.37
8
2.23
1.98
0.75
1.46
9
7.05
5.3
0.6
0.99
10
3.69
6.96
0.68
1.26
11
4.13
6.14
0.96
1.62
12
7.58
8.9
0.63
1.2
13
2.26
1.24
0.79
1.55
14
3.68
2.6
0.64
1.56
15
3.87
2.98
0.65
1.32
16
3.32
1.37
0.68
0.91
Median ()
3.65
2.60
0.68
1.32
value (pre- versus posttreatment)
0.30
<0.0001
Mann-Whitney test, 2-tailed; pretreatment versus posttreatment values.
